Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study

Satish K Garg, Mary K Voelmle, Christie R Beatson, Hayley A Miller, Lauren B Crew, Brandon J Freson, Rachel M Hazenfield, Satish K Garg, Mary K Voelmle, Christie R Beatson, Hayley A Miller, Lauren B Crew, Brandon J Freson, Rachel M Hazenfield

Abstract

Objective: To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months.

Research design and methods: Sixty type 1 diabetic adults with similar baseline characteristics, using either MDI (n = 30) or CSII (n = 30) therapy, were enrolled in this 6-month prospective study. Subjects were instructed to wear the DexCom SevenPLUS continuous glucose monitor at all times throughout the study. All subjects were initially blinded from the continuous glucose monitoring (CGM) glucose data. After 4 weeks of blinded CGM use, the CGM was unblinded, making glucose data available to the patient. The CGM remained in the unblinded state for the remainder of the study (20 weeks). Clinic visits occurred every 4 weeks, at which time A1C values were collected and CGM data were downloaded.

Results: Mean baseline (± SD) A1C was 7.61 (± 0.76) and 7.63 (± 0.68) for CSII and MDI, respectively (P > 0.05). Without any significant therapy change, A1C decrease at 12 weeks was similar in both groups (P = 0.03). When compared with the blinded phase, unblinded use of CGM was associated with similar but significant reductions in glycemic control and variability parameters. In addition, both therapy groups had similar changes in mean glucose and glucose variability indexes at 3 and 6 months (ITT analysis, P > 0.05). Predefined per protocol analysis (sensor use at least 6 days/week) showed greater improvement in time spent in target range glycemia, 3.9-10.0 mmol/L (70-180 mg/dL), in the CSII group.

Conclusions: We conclude that CGM provides similar benefits in glucose control for patients using MDI or CSII therapy.

Trial registration: ClinicalTrials.gov NCT01104142.

Figures

Figure 1
Figure 1
Changes in hypoglycemic excursions during the study period were similar in ITT (n = 60) (A) and per-protocol analysis (n = 34) (B).
Figure 2
Figure 2
Changes in hyperglycemic excursions during the study period were also similar in the ITT analysis (n = 60) (A). However, hyperglycemic excursions were significantly lower in the CSII group in the subgroup analysis (per-protocol analysis, n = 34, B).

References

    1. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
    1. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. Chase HP, Roberts MD, Wightman C, et al. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics 2003;111:790–794
    1. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003;111:933–938
    1. Tanenberg R, Bode B, Lane W, et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc 2004;79:1521–1526
    1. Tamborlane WV, Beck RW, Bode BW, et al. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–1476
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010;33:17–22
    1. Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006;29:2730–2732
    1. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999;46:183–190
    1. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care 2004;27:734–738
    1. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006;29:44–50
    1. Garg SK, Kelly WC, Voelmle MK, et al. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care 2007;30:3023–3025
    1. Rodbard D, Jovanovic L, Garg S. Responses to continuous glucose monitoring in patients with type 1 diabetes using multiple daily injections and insulin pumps. Diabetes Technol Ther 2009;11:757–765
    1. Moser EG, Crew LB, Garg SK. Role of continuous glucose monitoring in diabetes management. Avances en Diabetologia 2010;26:73–79
    1. Jenkins AJ, Krishnamurthy B, Best JD, et al. Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels: a randomized controlled trial. Diabetes Care 2010;33:1242–1248
    1. Hirsch IB. Algorithms for care in adults using continuous glucose monitoring. J Diabetes Sci Tech 2007;1:126–129
    1. Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther 2009;11:717–723
    1. Bergenstal RM, Tamborlane WV, Ahmann A, et al. STAR 3 Study Group Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311–320
    1. Hill NR, Hindmarsh PC, Stevens RJ, Stratton IM, Levy JC, Matthews DR. A method for assessing quality of control from glucose profiles. Diabet Med 2007;24:753–758
    1. Garg SK. The future of continuous glucose monitoring. Diabetes Technol Ther 2009;11(Suppl. 1):S1–S3
    1. Garg SK. Role of continuous glucose monitoring in patients with diabetes using multiple daily insulin injections. Infusystems USA 2009;6:9–14
    1. Blevins TC, Bode BW, Garg SK, et al. AACE Continuous Monitoring Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract 2010;16:730–745

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner